Skip to main content

Assessment of ARIA Sufficiency: Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)

    Basic Details
    Approval Date
    Friday, September 13, 2024
    Original Posting Date
    Health Outcome(s)
    injection-related reactions
    malignancy